SLC5A2 and type 2 diabetes mellitus: This meta-analysis is the first one that has demonstrated the greater efficacy with the combination therapy of ACEI/ARB and SGLT2 inhibitor in lowering MACE, CV death or HHF, and CKO compared to the ACEI/ARB monotherapy among T2DM patients.